SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case

SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study

Published:2017-08-15 Issue:11 Volume:73 Page:1409-1416
ISSN:0031-6970
Container-title:European Journal of Clinical Pharmacology
language:en
Short-container-title:Eur J Clin Pharmacol

Author:

Liu Ju-E,Liu Xiao-Ying,Chen Sheng,Zhang Yan,Cai Li-Yun,Yang Min,Lai Wei-Hua,Ren Bin,Zhong Shi-Long

Funder

National Nature Science Foundation of China

National key research and development program

Science and Technology Development Projects of Guangdong Province, China

Science and Technology Development Projects of Guangzhou, Guangdong

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://link.springer.com/article/10.1007/s00228-017-2318-z/fulltext.html

Reference31 articles.

1. Joy TR, Hegele RA (2009) Narrative review: statin-related myopathy. Ann Intern Med 150(12):858–868

2. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292(21):2585–2590. doi: 10.1001/jama.292.21.2585

3. Taha DA, De Moor CH, Barrett DA, Gershkovich P (2014) Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. Transl Res: J LabClin Med 164(2):85–109. doi: 10.1016/j.trsl.2014.01.013

4. El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, Saadeh R, Saydam M (2011) Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve 44(6):877–881. doi: 10.1002/mus.22205

5. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359(8):789–799. doi: 10.1056/NEJMoa0801936

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Genetic Blueprint of Cardiovascular Therapy: Pharmacogenomics for Improved Efficacy and Safety;Journal of Indian College of Cardiology;2024-07

2. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism;Archives of Pharmacal Research;2023-12-30

3. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?;European Journal of Medical Research;2023-09-27

4. Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban;Scientific Reports;2023-09-25

5. Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review;Asian Biomedicine;2023-06-01